Financial Performance - In Q1 2024, the company achieved revenue of CNY 10.774 billion, a year-on-year increase of 2.49% [1] - The net profit attributable to shareholders reached CNY 1.702 billion, up 12.12% year-on-year [1] - For the full year 2023, total revenue was CNY 39.111 billion, an increase of 7.19% from CNY 36.488 billion in 2022 [1] - The net profit attributable to shareholders for 2023 was CNY 4.094 billion, a significant rise of 36.41% [1] - Basic earnings per share for 2023 were CNY 2.29, with a return on equity of 10.51%, up 2.64 percentage points from the previous year [1] Growth Drivers - The rapid revenue growth in the pharmaceutical segment is attributed to collaborations with institutions for clinical research, enhancing product lifecycle and market potential [2] - Marketing strategies included large-scale promotions and partnerships with chain pharmacies, leading to increased industrial chain performance [2] - Organizational improvements through talent development initiatives have enhanced management efficiency and product quality [2] Product Performance - The sales of the anti-hair loss product line "Yangyuanqing" exceeded CNY 300 million in 2023, marking a 36% year-on-year growth [3] - During the "Double 11" shopping festival, "Yangyuanqing" achieved significant online sales, ranking first in the domestic anti-hair loss category on platforms like Tmall and Douyin [4] Future Plans - The Traditional Chinese Medicine (TCM) resource segment aims to build a stable and high-quality supply chain for local medicinal materials, focusing on user needs and resource development [5] - The brand medicine sector plans to expand by leveraging the advantages of Yunnan's medicinal materials and enhancing processing capabilities [5] - The natural plant extraction segment will focus on sustainable development and market share expansion through innovative production techniques [5] - The pharmaceutical service segment will develop comprehensive solutions for TCM, enhancing market presence and creating a competitive advantage in the herbal medicine sector [5]

Group 1: Sales Performance - In 2023, Yunnan Baiyao toothpaste held a domestic market share of 24.60%, maintaining the top position in the market [2] - During the "Double 11" shopping festival, Yunnan Baiyao's flagship store on Tmall achieved over 100 million in sales for the first time, becoming the first flagship store to reach this milestone with a single toothpaste product [2] - Other traditional Chinese medicine products, such as Pudilan Anti-inflammatory Tablets and Huoxiang Zhengqi Water, achieved sales revenues exceeding 100 million, with year-on-year growth of approximately 16% and 124%, respectively [4] Group 2: Marketing Strategies - The company employs a dual approach of online and offline marketing to enhance brand exposure and expand market share [2] - Online strategies include collaborations with major e-commerce platforms and creative live streaming on platforms like Douyin [2] - Offline promotions included over 14,700 events across 1,465 cities, enhancing brand visibility through various campaigns [3] Group 3: Future Outlook - The company aims to position itself as a comprehensive health solution provider, focusing on the pharmaceutical industry and strengthening its core competencies [5] - Future strategies will emphasize the core position of traditional Chinese medicine, enhancing the competitive capacity of the entire industry chain [5] - The company plans to develop a strategic investment capability and risk management system to support healthy and efficient growth of core and innovative businesses [6] Group 4: R&D Progress - Yunnan Baiyao's subsidiary received approval for clinical trials of Fluorobufen Gel Patch, which is intended for pain relief and anti-inflammatory treatment [6]

Group 1: Investor Relations Activity - The investor relations activity was categorized as a phone survey [1] - Participants included representatives from Hongtu Innovation Fund [1] - The meeting took place on May 31, 2024, at the company's headquarters [1] Group 2: Meeting Purpose - The main purpose of the meeting was to understand the company's production and operational status [1] - The meeting involved discussions with the company's securities affairs representative and investor relations management [1]

Financial Performance - In Q1 2024, the company achieved a revenue of 10.774 billion CNY, a year-on-year increase of 2.49% [2] - The net profit attributable to shareholders was 1.702 billion CNY, up 12.12% year-on-year [2] - The basic earnings per share reached 0.95 CNY, reflecting an 11.76% increase [2] - The weighted average return on equity was 4.18%, an increase of 0.31 percentage points year-on-year [2] Core Product Sales - The core product series maintained a strong growth trend in 2023, with a gross margin of 70.6% [3] - Sales revenue from Yunnan Baiyao aerosol exceeded 1.7 billion CNY, growing by 15.27% year-on-year [3] - Other products, including Yunnan Baiyao adhesive bandages and ointments, also reported significant sales, with revenues over 900 million CNY and 600 million CNY respectively [3] Herbal Material Pricing Impact - The Chinese herbal resources division generated 1.71 billion CNY in external revenue, a year-on-year increase of approximately 22% [4] - The external sales of the herb Sanqi saw a substantial growth of 81% [4] - Despite a general increase in herbal material prices, the company's input material price increase was significantly lower than the industry average, which rose by 17.3% [4] Dividend Distribution - In 2023, the dividend plan was set at 20.77 CNY per 10 shares, totaling 3.706 billion CNY, which accounted for 90.53% of the net profit attributable to shareholders [5] - The company has consistently paid dividends for 31 years since its listing, with cumulative cash dividends exceeding 24.4 billion CNY [5]

云南白药集团股份有限公司 投资者调研会议记录表 编号：28-2405-14 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 ☑现场参观 □一对一沟通 □其他（电话会议） 参与单位名称及人员 贝莱德-杜章鸣 姓名 时间 2024年5月30日 地点 集团总部办公大楼 董事会秘书-钱映辉、证券事务代表-李孟珏、投资者关系管理 上市公司接待人员 -张昱 投资者关系活动主要 了解公司生产经营情况等相关问题 内容介绍 ...

云南白药集团股份有限公司 投资者调研会议记录表 编号：29-2405-15 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 ☑其他（电话调研） 参与单位名称及人员 彬元资本-钱璎、张颖恒 姓名 中信建投-袁全 时间 2024年5月30日 地点 集团总部办公大楼 上市公司接待人员 投资者关系管理-杨可欣、张昱 投资者关系活动主要 了解公司生产经营情况等相关问题 内容介绍 ...

Financial Performance - In Q1 2024, the company achieved revenue of CNY 10.774 billion, a year-on-year increase of 2.49% [1] - The net profit attributable to shareholders was CNY 1.702 billion, up 12.12% year-on-year [1] - For the full year 2023, total revenue reached CNY 39.111 billion, an increase of 7.19% from CNY 36.488 billion in 2022 [1] - The net profit attributable to shareholders for 2023 was CNY 4.094 billion, a significant increase of 36.41% [1] - Basic earnings per share for 2023 were CNY 2.29, up from the previous year [1] R&D Strategy - The company is focusing on short, medium, and long-term R&D projects driven by market needs and national policies [2] - Short-term goals include secondary innovation of existing products and rapid development of drug-device combinations [2] - Medium-term plans involve the development of innovative traditional Chinese medicine (TCM) and transdermal preparations [2] - Long-term focus is on the transformation of innovative drug R&D results and the development of multiple innovative drugs [2] Sales Performance - In 2023, the pharmaceutical segment generated revenue of CNY 6.481 billion, a growth of 8.16% [3] - The gross margin for core products was 70.6%, with significant contributions from Yunnan Baiyao aerosol sales exceeding CNY 1.7 billion [3] - Other TCM products also showed strong growth, with sales of Pudilan and Huoxiang Zhengqi Water increasing by nearly 16% and 124%, respectively [3] Online Market Strategy - In 2023, the health products segment achieved revenue of CNY 6.422 billion, a year-on-year increase of 6.50% [5] - Yunnan Baiyao toothpaste held a 24.60% market share in the domestic market, maintaining the leading position [5] - The company leveraged major online shopping events to boost sales, achieving record-breaking performance on platforms like Tmall and Douyin [5] 2024 Business Outlook - The company aims to focus on core businesses and sustainable growth, emphasizing "growth" and "efficiency" [6] - Plans include optimizing product and industry structures to create new growth points [6] - The strategy involves enhancing competitiveness across the entire supply chain and achieving cost reduction and efficiency improvement [6]

云南白药集团股份有限公司 投资者调研会议记录表 编号：27-2405-13 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 ☑其他（电话调研） 参与单位名称及人员 淳厚基金-薛莉丽、陈文、廖辰轩、顾伟、严定安、张倬颖 姓名 光大证券-黄素青 时间 2024年5 月29日 地点 集团总部办公大楼 上市公司接待人员 证券事务代表-李孟珏，投资者关系管理-杨可欣、张昱 投资者关系活动主要 了解公司生产经营情况等相关问题 内容介绍 ...

云南白药集团股份有限公司 投资者调研会议记录 时间：2024 年 5 月 29 日 地点：集团总部办公大楼 召开方式：电话调研 投资者：淳厚基金-薛莉丽、陈文、廖辰轩、顾伟、严定安、张 倬颖，光大证券-黄素青 参加人员：证券事务代表-李孟珏，投资者关系-杨可欣、张昱 会议内容 1、请介绍一下公司 2024 年一季度和 2023 年年度业绩情况。 答：2024年一季度，公司实现营业收入107.74亿，同比增长2.49%； 归母净利润 17.02 亿元，同比增长 12.12%；归母扣非净利润 16.90 亿元，同比增长20.51%；基本每股收益0.95元/股，同比增长11.76%； 加权平均净资产收益率 4.18%，同比增加 0.31 个百分点。 2023 年，公司全年实现营业收入 391.11 亿元，较上年同期的 364.88 亿元净增 26.23 亿元，增幅 7.19%，其中工业收入增速 7.58%； ...

云南白药集团股份有限公司（以下简称"云南白药"或"公司"）第十届 监事会 2024 年第三次会议（以下简称"会议"）于 2024 年 5 月 24 日以通讯 表决方式召开，本次会议通知于 2024 年 5 月 22 日以书面、邮件方式发出， 应出席监事 3 名，实际出席监事 3 名。本次会议的召集、召开程序符合《中 华人民共和国公司法》（以下简称"《公司法》"）、《公司章程》的相关规 定，会议合法有效。会议审议通过如下议案： 一、审议通过《关于选举第十届监事会股东监事的议案》 公司监事会于近日先后收到监事会主席游光辉先生以及监事会副主席 钟杰先生的书面辞职报告。游光辉先生因工作调整，申请辞去公司第十届监 事会监事及监事会主席的职务，游光辉先生的辞职申请自送达监事会之日起 生效；钟杰先生因达到法定退休年龄，申请辞去云南白药第十届监事会监事、 监事会副主席以及在云南白药及其控股子公司的一切职务，因钟杰先生辞职 将导致监事会成员低于法定最低人数，钟杰先生将履行职责至公司股东大会 选举产生新任监事之日。 依据《公司法》《公司章程》等相关法律法规及规范性文件规定，为确 保公司监事会成员不低于法定最低人数，完善公司监事会 ...